CervoMed Inc.
Price data unavailable
Track CRVO in your trading journalAbout CervoMed Inc.
CRVO is the ticker symbol for CervoMed Inc., a publicly traded US company.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Key metrics include a return on equity of -75.0%, a debt-to-equity ratio of 0.42.
The company reports trailing twelve-month revenue of $0 and net loss of $7.96M.
FINOTAUR aggregates real-time and fundamental data on CRVO to help traders and investors make informed decisions. Track CRVO in your trading journal alongside other positions for a unified view of your portfolio.
Fundamentals
| Revenue (TTM) | $0 |
| Net Income (TTM) | $-7.96M |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | -75.02% |
| Debt-to-Equity | 0.42 |
| Dividend per Share | — |
Recent News
- GlobeNewswire Inc.·Feb 18
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis
- GlobeNewswire Inc.·Dec 4
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
- GlobeNewswire Inc.·Dec 2
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
Want real-time analysis on CRVO?
Track it free in your trading journal. Log trades, tag setups, and review your edge.